RESTORE-G Data: 40% of T2DM Patients on GLP-1 RA Require Intensification After 2 Years
by dr. Alfredo Bambang, MBA
| 17 December 2024
The latest guidelines from the American Diabetes Association (ADA) set a target HbA1c level below 7% as the primary goal for most people with diabetes.¹ Despite this, many patients have not achieved this target with current therapies. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly popular in high-risk diabetes patients due to their cardiorenal protective effects, monotherapy with GLP-1 RAs often falls short of achieving the desired HbA1c target.²
